WO2004062666A3 - Use of rho-kinase inhibitorrs for treatment of benign prostatic hyperplasia - Google Patents

Use of rho-kinase inhibitorrs for treatment of benign prostatic hyperplasia Download PDF

Info

Publication number
WO2004062666A3
WO2004062666A3 PCT/GB2004/000139 GB2004000139W WO2004062666A3 WO 2004062666 A3 WO2004062666 A3 WO 2004062666A3 GB 2004000139 W GB2004000139 W GB 2004000139W WO 2004062666 A3 WO2004062666 A3 WO 2004062666A3
Authority
WO
WIPO (PCT)
Prior art keywords
rho
kinase
benign prostatic
prostatic hyperplasia
inhibitorrs
Prior art date
Application number
PCT/GB2004/000139
Other languages
French (fr)
Other versions
WO2004062666A2 (en
Inventor
Rowland Rees
Selim Cellek
Original Assignee
Univ London
Rowland Rees
Selim Cellek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London, Rowland Rees, Selim Cellek filed Critical Univ London
Publication of WO2004062666A2 publication Critical patent/WO2004062666A2/en
Publication of WO2004062666A3 publication Critical patent/WO2004062666A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Rho-kinase inhibitors are used to treat benign prostatic hyperplasia in man. Such inhibitors have a dual effect: they can relax the smooth muscle of the prostate and reduce the size of the prostate by inhibiting smooth muscle cell proliferation. A suitable Rho-kinase inhibitor is (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride.
PCT/GB2004/000139 2003-01-16 2004-01-16 Use of rho-kinase inhibitorrs for treatment of benign prostatic hyperplasia WO2004062666A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0301016.2A GB0301016D0 (en) 2003-01-16 2003-01-16 Treatment of benign prostatic hyperplasia
GB0301016.2 2003-01-16

Publications (2)

Publication Number Publication Date
WO2004062666A2 WO2004062666A2 (en) 2004-07-29
WO2004062666A3 true WO2004062666A3 (en) 2004-10-07

Family

ID=9951274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/000139 WO2004062666A2 (en) 2003-01-16 2004-01-16 Use of rho-kinase inhibitorrs for treatment of benign prostatic hyperplasia

Country Status (2)

Country Link
GB (1) GB0301016D0 (en)
WO (1) WO2004062666A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520323C (en) * 2003-04-09 2013-07-09 Exelixis, Inc. Tie-2 modulators and methods of use
CR9465A (en) * 2005-03-25 2008-06-19 Surface Logix Inc PHARMACOCINETICALLY IMPROVED COMPOUNDS
CN105367555B (en) * 2014-08-07 2019-06-25 广东东阳光药业有限公司 Substituted heteroaryl compound and combinations thereof and purposes
JPWO2017150174A1 (en) * 2016-03-04 2019-06-13 株式会社 シンスター・ジャパン Pharmaceutical composition containing 2,4-diaminoquinazoline derivative or a salt thereof as an active ingredient, and 2,4-diaminoquinazoline derivative having a specific structure
WO2019133022A1 (en) * 2017-12-30 2019-07-04 Aiviva Biopharma Inc. Multikinase inhibitors and uses in prostatic hyperplasia and urinary tract diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
EP1174150A1 (en) * 1999-04-22 2002-01-23 Mitsubishi Pharma Corporation Preventives/remedies for angiostenosis
US6399115B2 (en) * 1999-09-10 2002-06-04 Glenn Braswell Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
WO2003106450A1 (en) * 2002-06-17 2003-12-24 Bayer Aktiengesellschaft Phenylaminopyrimidines and their use as rho-kinase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
EP1174150A1 (en) * 1999-04-22 2002-01-23 Mitsubishi Pharma Corporation Preventives/remedies for angiostenosis
US6399115B2 (en) * 1999-09-10 2002-06-04 Glenn Braswell Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
EP1403255A1 (en) * 2001-06-12 2004-03-31 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
WO2003106450A1 (en) * 2002-06-17 2003-12-24 Bayer Aktiengesellschaft Phenylaminopyrimidines and their use as rho-kinase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADAM ROSALYN: "Rho-kinase inhibitors: potential therapeutics for benign prostate hyperplasia.", THE JOURNAL OF UROLOGY. UNITED STATES DEC 2003, vol. 170, no. 6 Pt 1, December 2003 (2003-12-01), pages 2523 - 2524, XP009029764, ISSN: 0022-5347 *
REES ROWLAND W ET AL: "Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells.", THE JOURNAL OF UROLOGY. UNITED STATES DEC 2003, vol. 170, no. 6 Pt 1, December 2003 (2003-12-01), pages 2517 - 2522, XP009029765, ISSN: 0022-5347 *
SOMLYO A V ET AL: "Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants.", MOLECULAR BIOLOGY OF THE CELL, vol. 13, no. Supplement, November 2002 (2002-11-01), 42nd Annual Meeting of the American Society for Cell Biology;San Francisco, CA, USA; December 14-18, 2002, pages 548a, XP009029938, ISSN: 1059-1524 *
SOMLYO A V ET AL: "Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 24 MAR 2000, vol. 269, no. 3, 24 March 2000 (2000-03-24), pages 652 - 659, XP002277882, ISSN: 0006-291X *

Also Published As

Publication number Publication date
GB0301016D0 (en) 2003-02-19
WO2004062666A2 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
WO2004105757A3 (en) Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
MX2009006864A (en) Novel jnk inhibitors.
MX2009010946A (en) Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis.
IL191832A (en) Pyridiazinone compounds and their use in the preparation of medicaments for treating tumours
WO2006052718A8 (en) Farnesyltransferase inhibitors for treating sepsis
AU2483000A (en) Treatment of asthma with mek inhibitors
TW200510311A (en) CCr8 inhibitors
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
NO20025601L (en) Arylmethylamine derivatives for use as tryptase inhibitors
HK1066482A1 (en) Use os fucans in the treatment of adhesions, arthritis and psoriasis
MXPA06000933A (en) Aminopyrazole compounds and use as chk1 inhibitors.
TNSN07385A1 (en) Therapeutic combination in case of benign prostate hyperplasia
NZ545506A (en) Therapeutic agents useful for treating pain
NO20071378L (en) Thiazolo-naphthyl acids.
ATE424208T1 (en) PROTEIN KINASE INHIBITORS
JO2473B1 (en) Payrazoles as Inhibitors of Tumor ‎Necrosis Factor.‎
MXPA05013536A (en) Pyrrolidin-1, 2- dicarboxylic acid- 1- [(4- ethinyl- phenyl) - amid]- 2- [(phenyl)- amid] derivative as inhibitors of coagulation factor xa and viia for the treatment of thrombosis.
MY138732A (en) Conjugated complement cascade inhibitors
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
WO2003024386A8 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
WO2003106450A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
WO2003004006A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
WO2004062666A3 (en) Use of rho-kinase inhibitorrs for treatment of benign prostatic hyperplasia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase